Correlation Between Unicycive Therapeutics and Plus Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Plus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Plus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and Plus Therapeutics, you can compare the effects of market volatilities on Unicycive Therapeutics and Plus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Plus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Plus Therapeutics.

Diversification Opportunities for Unicycive Therapeutics and Plus Therapeutics

-0.4

Correlation Coefficient

Unicycive Therapeutics  Plus Therapeutics

Very good diversification

The 3 months correlation between Unicycive and Plus is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Plus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plus Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Plus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plus Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Plus Therapeutics go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Plus Therapeutics

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.45 times more return on investment than Plus Therapeutics. However, Unicycive Therapeutics is 1.45 times more volatile than Plus Therapeutics. It trades about 0.28 of its potential returns per unit of risk. Plus Therapeutics is currently generating about -0.04 per unit of risk. If you would invest  50.00  in Unicycive Therapeutics on September 2, 2024 and sell it today you would earn a total of  19.00  from holding Unicycive Therapeutics or generate 38.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Unicycive Therapeutics  vs.  Plus Therapeutics

Unicycive Therapeutics

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Plus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Plus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Plus Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Unicycive Therapeutics and Plus Therapeutics

The main advantage of trading using opposite Unicycive Therapeutics and Plus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Plus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plus Therapeutics will offset losses from the drop in Plus Therapeutics' long position.

The idea behind Unicycive Therapeutics and Plus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.